{"id":19926,"date":"2023-04-07T21:43:00","date_gmt":"2023-04-07T13:43:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19926"},"modified":"2024-12-26T21:49:39","modified_gmt":"2024-12-26T13:49:39","slug":"junshi-biosciences-challenges-alynlams-pcsk9-sirna-patent-with-cnipa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19926","title":{"rendered":"Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA"},"content":{"rendered":"\n

Junshi Biosciences (SHA: 688180<\/a>) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis.<\/p>\n\n\n\n

CNIPA Oral Proceedings and Patent Dispute<\/strong>
According to a notification on oral proceedings recently issued by the China National Intellectual Property Administration (CNIPA), Junshi is seeking to invalidate an invention patent originally filed by US-based Alnylam Pharmaceutical (patent no. 2013800639305) named “PCSK9 iRNA composition and its use method”. The invalidation declaration was filed by an individual named Li Caihui, identified as an IP executive at Junshi.<\/p>\n\n\n\n

Details of the Contested Patent<\/strong>
The patent in question involves RNAi agents targeting the PCSK9 gene, including double-stranded RNAi agents, as well as methods for using such RNAi agents to inhibit PCSK9 expression and methods for treating subjects with lipid disorders, such as hyperlipidemia. The application for this invention patent was made on December 5, 2013.<\/p>\n\n\n\n

PCSK9-targeted Therapies and Market Landscape in China<\/strong>
The PCSK9 target is a popular focus in the field of lipid-lowering drugs. Currently, there are two imported anti-PCSK9 monoclonal antibodies approved for sale in China: Amgen\u2019s Repatha (evolocumab) and Sanofi’s Praluent (alirocumab). No domestic anti-PCSK9 drug has been approved yet.<\/p>\n\n\n\n

Alnylam’sPCSK9-targeted siRNA Therapy and Novartis<\/strong>
Alnylam was responsible for discovering and developing the PCSK9-targeted siRNA inclisiran, which it licensed to The Medicines Company. Novartis later acquired the drug via its 2019 acquisition of The Medicines Co., for USD 9.7 billion. Inclisiran was first approved in Europe as a treatment for adult hypercholesterolemia and mixed dyslipidemia in December 2020 and gained US approval in 2021. The drug requires only two injections each year to achieve lipid-lowering effects, compared with the weekly subcutaneous injections of PCSK9-targeted competitors or daily use of statins. Novartis filed inclisiran for approval in China in November 2021 and expects a regulatory decision in the second half of 2023, as per the Swiss giant\u2019s Q4 2022 financial report.<\/p>\n\n\n\n

Junshi Biosciences’ PCSK9-targeted Pipeline<\/strong>
In terms of Junshi’s activity in the PCSK9 space, the firm\u2019s annual report for 2022 shows that ongericimab (code JS002), a PCSK9-targeted monoclonal antibody, is set for a market approval filing later this year. Junshi also has a siRNA drug research and development platform, with one RNAi drug (code JS401) targeting angiopoietin-like protein 3 messenger RNA in the clinic.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[2175,296,73,64,900],"class_list":["post-19926","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","tag-alynlam-pharmaceutical","tag-junshi-biosciences","tag-patents","tag-rnai-aso","tag-sha-688180"],"yoast_head":"\nJunshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19926\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19926\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-07T13:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-26T13:49:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA\",\"datePublished\":\"2023-04-07T13:43:00+00:00\",\"dateModified\":\"2024-12-26T13:49:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926\"},\"wordCount\":408,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alynlam Pharmaceutical\",\"Junshi Biosciences\",\"Patents\",\"RNAi \\\/ ASO\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19926#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19926\",\"name\":\"Junshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-07T13:43:00+00:00\",\"dateModified\":\"2024-12-26T13:49:39+00:00\",\"description\":\"Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19926\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19926#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA - Insight, China's Pharmaceutical Industry","description":"Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19926","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19926","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-07T13:43:00+00:00","article_modified_time":"2024-12-26T13:49:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19926#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19926"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA","datePublished":"2023-04-07T13:43:00+00:00","dateModified":"2024-12-26T13:49:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19926"},"wordCount":408,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alynlam Pharmaceutical","Junshi Biosciences","Patents","RNAi \/ ASO","SHA: 688180"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19926#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19926","url":"https:\/\/flcube.com\/?p=19926","name":"Junshi Biosciences Challenges Alynlam's PCSK9 siRNA Patent with CNIPA - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-07T13:43:00+00:00","dateModified":"2024-12-26T13:49:39+00:00","description":"Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by Alynlam Pharmaceutical related to the development of PCSK9-targeted small-interfering RNA (siRNA) therapies, such as the lipid-lowering drug Leqvio (inclisiran), which is now marketed globally by Novartis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19926#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19926"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19926#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19926"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19926\/revisions"}],"predecessor-version":[{"id":19928,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19926\/revisions\/19928"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}